Your margin is decided at signing, not at scale
In a telehealth business, your marketing decides your revenue and your contract decides your margin. Two brands with the same audience, the same treatments, and the same retail prices can keep very different amounts of money — purely because of how the platform underneath them charges. That difference does not show up in the demo; it shows up on month three's statement.
The mistake most partners make is evaluating platforms on features and vibes, then treating the fee structure as fine print. It is the opposite of fine print. The fee structure determines whether the work you do on pricing, conversion, and retention accrues to you or to your vendor.
This guide gives you the frame to run that evaluation: what you are actually renting versus owning, how the three common fee models behave, why flat product rates change the incentive math, and which levers move lifetime value once you are live.
The rent-vs-own frame
Every telehealth operation is built from the same layers: software, clinicians, pharmacy fulfillment, payments, support, and compliance. For each layer, someone owns it and everyone else rents it. Rent is not evil — it is how you start fast — but every rented layer has a landlord, and every landlord prices in a margin.
The problem is that the rents stack. A tech platform marks up its software, sources clinicians from a network that marks up the consult, and routes prescriptions through a fulfillment partner that marks up the fill. By the time a patient's payment reaches you, three landlords have taken their cut, and your spread is what is left over.
So the first diligence question is not about features. It is about ownership: for each layer of the stack, does this platform own it, or is it passing through someone else's markup with its own on top?
- Rented software: per-seat or license fees that scale with your team, not your revenue
- Rented clinicians: a third-party network's consult rate, marked up on the way to you
- Rented fills: reseller pharmacy pricing, where the fulfillment margin belongs to someone else
Rent compounds. Each rented layer is a separate margin taken before you see a dollar — and none of it gets cheaper as you grow.
The three fee structures you will meet in the market
Most platforms charge one of three ways, and each maps loosely to a category of vendor. Revenue share is common among clinical-network vendors: the platform takes a percentage of your topline. It sounds aligned, but it aligns the platform with your revenue, not your margin — every improvement you make to retail pricing or conversion raises their take alongside yours, forever.
Per-seat and license pricing is the infrastructure-only pattern: a predictable software bill, with everything operational left as your problem. You still have to source and pay clinicians, negotiate pharmacy fulfillment, stand up support, and carry compliance. The software line looks cheap because the expensive lines are missing from it.
Flat product rates are the third model: a fixed price per unit of care — per visit, per treatment cycle — regardless of what you charge the patient. The platform's revenue scales with your volume, and your margin scales with your pricing. It is also the only one of the three where you can compute your per-unit economics before you sign, because the rate is a number rather than a percentage of an unknown.
- Revenue share: platform takes a percentage of topline — your pricing power works for them
- Per-seat / license: predictable software cost, but clinicians, pharmacy, and support are extra
- Flat product rates: fixed cost per unit of care — your retail and your spread are yours
Why flat rates plus partner-set retail align incentives
Embed Care charges a flat monthly platform fee plus a flat rate per product. That is the whole model — no revenue share, no equity, no seat licenses. Virtual-care visits carry one flat rate. Peptide protocols are flat per 28-day cycle across entry, core, and premium tiers, medication included. GLP-1 programs are flat for life, medication included. The rates themselves are scoped to your program on a call.
You set the patient's retail price inside a floor and a cap, and every dollar of spread between your retail and the flat rate is yours. The floor protects the category from race-to-the-bottom pricing; the cap protects patients. Between them, your margin is a decision you make, not a residual you discover.
The incentive math is the point. When the platform's rate is flat, its only way to earn more is for you to sell more — its incentive is your volume, not your upside. Raise your prices, improve your funnel, or cut your churn, and the platform's take does not move. Under a revenue share, every one of those wins is taxed.
Flat rates make the platform's incentive your volume. Revenue share makes its incentive your upside. Pick the one you want compounding for a decade.
How to model your numbers without fooling yourself
The honest way to model a telehealth P&L is per unit, then per relationship. Per unit: your retail minus the flat product rate is your spread on each visit or cycle. Per relationship: that spread multiplied by how many months a patient stays, plus whatever else they buy along the way. Everything else — audience size, conversion rate, care-line mix — just scales those two numbers.
Three inputs dominate the model, and you should stress-test all of them: how much of your audience converts to a first purchase, which care lines they land on, and how many refill cycles they stay. The third input moves the answer more than the other two combined, which is why the retention section below matters more than any launch-week projection.
We publish an interactive calculator on the pricing page that runs this exact math against your own audience assumptions — plug in your numbers rather than trusting anyone's example. And treat every output for what it is: a model of what the structure makes possible, not a promise of what you will earn. Any vendor quoting your results before knowing your audience is selling, not modeling.
Churn and LTV: the levers that actually move
Acquisition gets the attention, but telehealth economics are decided by the refill. A patient who stays subscribed pays the acquisition cost once and delivers spread every cycle after, which is why a point of retention is worth more than a point of conversion in almost every realistic model.
The structural lever is the price ladder. A low-cost visit is a low-friction way to start a clinical relationship across your whole list; entry-tier protocols convert that relationship into a first subscription; higher tiers and GLP-1 programs carry the long-run value. Patients who enter on a low rung and climb are worth multiples of patients who buy once, and the ladder only works if every rung is switched on.
The second lever is whole-person care. Single-condition clinics churn when the first journey ends — the weight-loss patient finishes and leaves. Switching on adjacent care lines gives that patient somewhere to go next and turns one journey into a lasting clinical relationship — the strongest retention shape we know of in this category.
The third lever is machinery: refill reminders, lapsed-patient winback, cart recovery, onboarding sequences. None of it is glamorous and all of it moves LTV. It ships built into Embed Care rather than as a project on your roadmap.
The pharmacy layer is the margin keystone
Every recurring treatment has a cost base, and whoever owns that cost base owns the pricing power. A platform that rents its fills from a third-party pharmacy pays reseller prices, adds its own margin, and hands you the total. You cannot out-negotiate a supply chain you are three layers removed from.
This is why Embed Care runs on RX Route, our owned pharmacy supply layer, integrated across 7 compounding pharmacies. Every fill is scored for stock, cost, and delivery speed, then routed down the best path automatically. Because the cost base is ours, the flat rates can stay flat — and the margin headroom sits on your side of the table.
When you diligence any platform, make the pharmacy question explicit: who owns the supply relationship, and whose margin lives inside the fill? One note that applies to this whole category: compounded medications are not FDA-approved, they are prescribed at a licensed clinician's discretion, and not all patients qualify.
Software margins are visible on the invoice. Pharmacy margins hide inside the fill — and the fill is where recurring-revenue economics are won or lost.
The questions to bring to any platform
You now have the frame; here is the checklist. Put these questions to every vendor, including us, and insist on numbers rather than adjectives. A platform with good unit economics will answer in rates; a platform with bad ones will answer in stories.
On our side of the table, the answers come from having operated this model first. Embed Care is built by the operators behind DirectMeds and TelMDFirst — two LegitScript-certified, first-party telehealth brands that together have served more than a million patients and generated $250M+ in revenue on this same infrastructure, with patient-rated care at 4.6/5. Beyond those brands, the team's combined DTC telehealth track record exceeds $1B in sales.
The structural pieces are flat statements: LegitScript-certified, HIPAA-compliant, a credentialed clinician network in all 50 states, and a partner storefront that goes live in days. The economics are the part you should pressure-test hardest — because they are the part you will live with longest.
- How do you charge — revenue share, per-seat, or flat product rates — and what is the number?
- Who sets patient retail prices, and is there a floor and cap or a mandated price?
- Who owns the pharmacy supply, and whose markup is inside each fill?
- Who employs or contracts the clinicians, and in how many states?
- What retention machinery ships on day one versus lands on my roadmap?
- Have you run this model on your own brands, and what happened?
Frequently asked
- How does Embed Care make money?
- A flat monthly platform fee plus a flat rate per product — virtual-care visits, peptide protocols per 28-day cycle, and GLP-1 programs, with medication included in the program rates. No revenue share, no equity, no seat licenses. The specific rates are set in your signed partner agreement.
- Who sets the prices patients pay?
- You do. Partners set retail inside a floor and a cap, and the full spread between your retail and the flat product rate is yours. Our rates do not change when your prices do.
- Is medication included in the flat rates?
- For care programs, yes — peptide protocols are priced per 28-day cycle with medication included, and GLP-1 programs are one flat rate for life with medication included. Compounded medications are not FDA-approved, are prescribed at a licensed clinician's discretion, and not all patients qualify.
- Do you guarantee what I will earn?
- No, and you should distrust anyone who does. The calculator on our pricing page models what the fee structure makes possible under your own assumptions — outputs are illustrative models, not promises or guarantees.
- Why does owning the pharmacy layer matter for my margin?
- Because the fill is where recurring-revenue cost lives. A platform that rents fulfillment passes a reseller's markup through to you; Embed Care routes fills through RX Route, our owned supply layer across 7 compounding pharmacies, so the flat rates are priced from our cost base rather than someone else's.
- Do I need to hire clinicians or contract a pharmacy myself?
- No. Embed Care operates the full clinical stack behind your brand — a credentialed clinician network in all 50 states, pharmacy fulfillment, payments, support, and compliance — while you run the brand and the audience.
Want pricing for your program — and the Rx menu that goes with this?
The partner overview in one email; a human follows up with pricing scoped to your program.